.png)
OUR SERVICES
Our diverse areas of expertise are designed to fit the changing needs of your project
01.
ACCURATE MARKET SIZE ESTIMATIONS
Each drug, technology, or device is created with a specific disease(s) in mind. Within this population, severity of these conditions vary, with different stages requiring different levels of intervention. Understanding the way that these diseases or conditions are staged is fundamental to accurately characterizing market sizes.
02.
ADOPTION CONCERNS, SPECIFICALLY RELATING TO PHYSICIAN IMPLEMENTATION
Despite FDA approvals and company sponsors, physician adoption remains a significant challenge for companies bringing new technologies and interventions to the market. Our relationships with specialists in various specialties provide coveted insight into what experts are looking for in novel products, and how they are looking for it.
03.
COMPETITION ANALYSIS AT THE PRODUCT LEVEL
Describing medical technology as complicated radically underestimates the intricacy of both the product and the human body. Understanding the mechanisms by which these products function only becomes more complex as the number of similar devices increases. Sentinel Analytics is experienced in deriving a strategic advantage from evaluating competition, their technology, and intended patient populations.
04.
STANDARD OF CARE PRACTICES AND RELEVANT SHORTCOMINGS INCLUDING DIAGNOSTICS
In order to determine whether novel technologies can improve patient care, you must first understand how patients are treated under the current standard of care. Leveraging connections with specialists in conjunction with reviews of restricted access guidelines and publications, we provide an unmatched angle on modern therapies enabling your fund to make fully informed comparisons.
05.
HUMAN ANATOMY AND PHYSIOLOGY BACKGROUND
The existence of medical intervention is grounded in the anatomy and physiology of the human body. Without the body, a product is useless, and without a product, the body is less than optimized. Understanding how the human body functions enables us to evaluate the extent and possibility of benefits a new treatment can provide. Additionally, understanding how a product works is imperative for investor relations as it pertains to your portfolio.
06.
INTERPRETATION OF SCIENTIFIC PUBLICATIONS AND STUDIES
Disrupted markets represent large opportunities of capital growth. Targeting these major disruptions relies on the frequent review of literature to predict and detect the trajectory of treatments as they happen in live time. Whether it is reviewing data from a potential portfolio company, or evaluating a market as a whole, interpreting publications and reports serves as an important way to keep our fingers on the pulse of contemporary medicine.
07.
KOL IDENTIFICATION AND CONTACT/INTERVIEW/
QUESTIONING
Niche markets imply additional risk and technical challenges. Populations can be small but remain untapped, which can prove to be a lucrative and impactful field to invest in. With these small populations comes limited access to specialists who treat and monitor this population on a regular basis. The ties Sentinel Analytics LLC has with academia and health care practitioners opens back door access to specialists and conferences that would otherwise remain in the dark; this is in addition to deal flow sourcing.
08.
PRE-SCREENING OF DEAL FLOW ON A MARKET CONDITION AND TECHNOLOGICAL BASIS
As the climate of private equity is now, companies are struggling to raise capital across the board. As this struggle intensifies, companies proactively attempt to contact investment funds in a scramble to secure a series. With this occurrence comes a high volume of deal flow from unvetted and unknown sources. Our team enables your firm to sort through these companies in a methodical, organized manner, leaving no stones unturned.
09.
REGULATORY PATHWAY/PRECEDENT
FDA and CE approval represents a large fraction of healthcare startup expenditures, man hours, and investor scrutiny. Understanding the different kinds of approval pathways, the risks associated with each, as well as previous regulatory precedent is imperative to thoroughly evaluating and de-risking this major factor in company advancement.
10.
CLINICAL TRIAL EVALUATION
Whether it is a proof of concept animal study or a phase III trial, experimentation serves as one of the best sources of insight into product efficacy and safety profiles. Ensuring that study designs meet rigorous standards helps ensure that the validity and conclusions drawn from these experiments can be trusted, that capital is efficiently spent, and maximal data value can be extracted.
11.
IDENTIFICATION OF A TECHNOLOGICAL INFLECTION POINT
After negotiating the wide variety of factors both intrinsic and extrinsic to a healthcare company, timing your investment nearest to the inflection point makes your money work harder and faster. Determining when the growth phase of a product is nearing exponential growth enables the recognition of value inflection.
“You can dream, create, design, and build the most wonderful place in the world. But it requires people to make the dream a reality.”
WALT DISNEY